Avistone Pharmaceuticals Biotechnology

Explore the latest insights on Avistone Pharmaceuticals Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Avistone Pharmaceuticals Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Avistone Pharmaceuticals Biotechnology and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Avistone Pharmaceuticals Biotechnology's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Limited (HKG: 2137) announced the launch of its proprietary BRiSC (Bispecific RNAi iSilenCing) small interfering RNA (siRNA) drug discovery platform, designed to advance the development of next‑generation ribonucleic…

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

CompanyDrug

Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC

Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China
CompanyDrug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Avistone's Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC
CompanyDrug

Avistone’s Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
CompanyDeals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

CompanyDeals

Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development

CompanyDrug

Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China